TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2369474
Drug: Intravesical application
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical application of cephalotin in saline solution
Study: 22018220
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution only (control group)
Study: 31692188
Drug: galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: galcanezumab 120 mg
Study: 31692188
Drug: galcanezumab 240
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: galcanezumab 240 mg
Study: 19559427
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL cyanoacrylate injection (group A)
Study: 19559427
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL cyanoacrylate injection (group B)
Study: 11578673
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dosing (SDD) of antidepressants
Study: 11578673
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dosing (MDD) of antidepressants
Study: 8147945
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg slow release tablet, Aprical long)
Study: 3260059
Drug: Walking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking therapy
Study: 3260059
Drug: Sauna therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sauna therapy
Study: 23782948
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate, large isocaloric doses, duration 8 weeks
Study: 23782948
Drug: Rice protein
Normalized name: rice protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice protein isolate, large isocaloric doses, duration 8 weeks
Study: 15176685
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.i.d. for 8 weeks (Arm A)
Study: 15176685
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg t.i.d. (Arm B)
Study: 15176685
Drug: Placebo dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dextrose tablets (Arm C)
Study: 12738555
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol
Study: 11528262
Drug: Topical apraclonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical apraclonidine
Study: 9437230
Drug: GLP-1 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (400 micrograms buccal tablet)
Study: 3828171
Drug: Closed-loop computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop computer system delivering sodium nitroprusside infusion
Study: 12593178
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education programs for asthma; details on dosage and duration not specified.
Study: 12593178
Drug: Education programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education programs in COPD including self-management; details on dosage and duration not specified.
Study: 12593178
Drug: Cost effectiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost effectiveness of education programs for asthmatics; details on dosage and duration not specified.
Study: 10636350
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefotaxime sodium diluted in 100 mL of isotonic sodium chloride solution (Group A)
Study: 10636350
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of isotonic sodium chloride solution in 100 mL of saline (Group B)
Study: 4041323
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine solution 4 ml without glucose
Study: 4041323
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine solution 4 ml with glucose
Study: 24935040
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of mobilized BMSCs
Study: 24935040
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of mobilized BMSCs
Study: 24935040
Drug: Subcutaneous granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous granulocyte colony-stimulating factor injections
Study: 24935040
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections only
Study: 20400900
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 250 mg aspirin
Study: 8648016
Drug: Azelastine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (4 mg twice daily)
Study: 17239638
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelastine and montelukast
Study: 15315030
Drug: Azithromycin 1000
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1000 mg once a week
Study: 27583108
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (Group A)
Study: 18952538
Drug: OAT (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAT (omeprazole, amoxicillin, tinidazole)
Study: 17366797
Drug: Radiotherapy (LCAHFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (LCAHFR with total dose of 68.4-71.0 Gy)
Study: 11064608
Drug: Lidocaine 20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20.0 mg in 2.0 ml
Study: 11064608
Drug: Ketamine 5
Normalized name: ketamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 5 mg in 2.0 ml
Study: 11064608
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 2.0 ml
Study: 31977667
Drug: Low-dose estradiol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estradiol
Study: 31977667
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol tablet
Study: 20200432
Drug: Antioxidant micronutrient
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant micronutrient combination (800 mg dl‐alpha‐tocopherol acetate, 24 mg beta‐carotene, 1.0 g vitamin C, 200 microg l‐selenomethionine, 7.2 mg riboflavin, 80 mg niacin, 60 mg zinc, 5 mg manganese) given daily over 4 months
Study: 20200432
Drug: Antioxidant micronutrient
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant micronutrient combination
Study: 10499750
Drug: Neostigmine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (500 microg) + mepivacaine (500 mg)
Study: 10499750
Drug: Mepivacaine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (500 mg) + saline (0.9%, 1 mL)
Study: 6407402
Drug: Benoxaprofen 600
Normalized name: fenoprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen 600 mg orally daily for 8 weeks
Study: 24920891
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP; 500 μg twice daily for 6 months)
Study: 20962624
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (HD-IVIG)
Study: 20962624
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulin (low-IVIG)
Study: 11114219
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d OXC
Study: 11114219
Drug: 1200 mg/d
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/d OXC
Study: 11114219
Drug: 2400 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/d OXC
Study: 8788262
Drug: Dietary fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fish oil (FO) supplementation (5 food bars daily for 6 weeks)
Study: 1638170
Drug: brofaromine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: brofaromine (150 mg daily)
Study: 6465821
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin (50 mg)
Study: 6465821
Drug: Intravenous metamizole
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizole (2.5 g)
Study: 20463564
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (methylprednisolone)
Study: 29868796
Drug: Ozone (O2‐O3)
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone (O2‐O3) injection
Study: 21477416
Drug: Quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine IR (300 mg/d on days 9-12)
Study: 21477416
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (300 mg/d on days 5-8)
Study: 19500999
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Pro‐Stat 64 supplementation
Study: 19500999
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of Pro‐Stat 64 supplementation
Study: 16518128
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of methylphenidate
Study: 11020910
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg mesulid, Pfizer)
Study: 11020910
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg, Bayer)
Study: 9025767
Drug: MP therapy
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP therapy (MPH/PSL combination)
Study: 9025767
Drug: AT (alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT (alternating therapy with VMCP and MMPP)
Study: 8331248
Drug: Betaxolol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.25% ophthalmic suspension (preserved with benzalkonium chloride)
Study: 8331248
Drug: Betaxolol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.25% ophthalmic suspension (unpreserved)
Study: 3579256
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg every 6 h (five doses)
Study: 3579256
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg every 12 h (three doses)
Study: 28666964
Drug: Fournier® 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fournier® 200 mg capsule
Study: 28666964
Drug: Lipidil® 145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipidil® 145 mg tablet
Study: 28666964
Drug: HME 160
Normalized name: TRACH-VENT HME TELEFLEX #41112
Approvals — FDA: no, EMA: no, PMDA: no
Description: HME 160 mg tablet
Study: 27629349
Drug: Extracellular space
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracellular space contrast agents (ECSCAs)
Study: 27629349
Drug: Blood-pool contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-pool contrast agent (BPCA)
Study: 24429305
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment arm (ART within 12 weeks of initiating standard first-line anti-tuberculosis treatment)
Study: 24429305
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment arm (ART after completing anti-tuberculosis treatment)
Study: 22395586
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of essential oil of Melaleuca alternifolia and organically bound iodine (TTO-I)
Study: 10550740
Drug: sublingual‐swallow immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual‐swallow immunotherapy
Study: 8889480
Drug: H-wave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-wave therapy at 16 Hz
Study: 10583337
Drug: H-wave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-wave therapy at 60 Hz
Study: 10583337
Drug: H-wave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-wave therapy at 2 Hz
Study: 25724644
Drug: Pradigastat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat (100 mg for 3 days followed by 40 mg for 7 days, 1 hour before meal)
Study: 24582486
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 2 mg/mL per min) plus paclitaxel (60 mg/m(2)) every week for 18 weeks
Study: 24582486
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6 mg/mL per min) plus paclitaxel (175 mg/m(2)) every 3 weeks for six cycles
Study: 15507885
Drug: Oral defibrotide
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral defibrotide (800 mg/die)
Study: 11331472
Drug: Imipenem (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (1.0 g plus cilastatin intravenously 3 times a day)
Study: 11331472
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed antibiotics)
Study: 9425396
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant growth hormone (rhGH) replacement therapy at a dosage of 12.5 micrograms/kg/day (initial dosage during the first 4 weeks 6.25 micrograms/kg/day)
Study: 8245105
Drug: Non-acid-buffering prophylaxis
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-acid-buffering prophylaxis therapy (6 patients)
Study: 8245105
Drug: Standard antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antacid or antacid/H2 histamine-blocking agent combination prophylaxis therapy (13 patients)
Study: 25362221
Drug: Raloxifene, 60
Normalized name: Raloxifene, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene, 60 mg/d for 8 months
Study: 11979650
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin (Bactroban) applied to nares and catheter exit site
Study: 10023498
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 100 mg
Study: 10023498
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 250 mg
Study: 10023498
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 500 mg
Study: 7751428
Drug: Local phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local phentolamine (administered directly into a preconstricted hand vein)
Study: 7751428
Drug: Systemic phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic phentolamine (administered intravenously)
Study: 7751428
Drug: Control (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (vehicle solutions)
Study: 43755
Drug: Metoclopramide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 40 mg
Study: 27595728
Drug: 5% EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% EMLA cream
Study: 23370902
Drug: 0.5-mg intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg intravitreal ranibizumab
Study: 21550313
Drug: Cefotaxime infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime infusion plus paracetamol
Study: 21550313
Drug: Cefotaxime infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime infusion
Study: 21550313
Drug: Cefotaxime bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime bolus plus paracetamol
Study: 19189066
Drug: High-dose antithrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithrombin (AT) without simultaneous heparin treatment
Study: 19189066
Drug: High-dose antithrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithrombin (AT) without simultaneous heparin treatment in risk group grade II patients
Study: 17536000
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at 0.06 mg/kg.d for 2 years (group I)
Study: 17536000
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) for 12 months after 12 months of no treatment (group II)
Study: 14990550
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg of 0.9% NaCl infusion over 60 min
Study: 19459553
Drug: Ropivacaine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (150 mg)
Study: 11810323
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg or 5 mg)
Study: 11810323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5 mg morphine and 75 mg ropivacaine
Study: 9732164
Drug: ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebastine 10 mg
Study: 8054406
Drug: Lisuride (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (up to 4.0 mg daily for 3 weeks)
Study: 26510448
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily for 24 weeks
Study: 26510448
Drug: Metformin vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin vs Placebo
Study: 16601292
Drug: Subsequent endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent endocrine therapy after fulvestrant
Study: 3161487
Drug: tocainide HC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocainide HC1 900 mg/day
Study: 30501605
Drug: BPF Phyto
Normalized name: phytol
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPF Phyto (phytosomal formulation of bergamot polyphenolic fraction)
Study: 20383510
Drug: Labetalol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (2.5 mg in 20 ml saline)
Study: 21468614
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml saline)
Study: 20383510
Drug: Labetalol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (5 mg in 20 ml saline)
Study: 26365144
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave treatment (ESWT)
Study: 17432639
Drug: Antondine injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antondine injection (Control)
Study: 10641772
Drug: APD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD treatment
Study: 9032854
Drug: Gamma Knife
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Knife radiosurgery with a mean dose of 12.1 Gy
Study: 1647919
Drug: Continuous total
Normalized name: Zinc Oxide 7.25 g in 100 g / Titanium Dioxide 3.5 g in 100 g TOPICAL SPRAY [Kids SPF50 Plus Mineral Sunscreen Continuous Totally Tropical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous total parenteral nutrition (infused continuously over 24 h)
Study: 1647919
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (infused between 22.00 and 10.00 hours)
Study: 1647919
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Continuous and Cyclic total parenteral nutrition)
Study: 3910159
Drug: Lay open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lay open treatment (n = 26)
Study: 3910159
Drug: Excision treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excision treatment (n = 21)
Study: 27627782
Drug: Naltrexone hydrochloride,
Normalized name: Naltrexone Hydrochloride, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone hydrochloride, 50 mg/d
Study: 15762190
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment (50 mg/day for 9 days)
Study: 14696887
Drug: Ketorolac 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.35 mg x kg(‐1)
Study: 14696887
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg x kg(‐1)
Study: 14696887
Drug: Both Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Ketorolac and Morphine
Study: 1476266
Drug: Oral defibrotide
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral defibrotide in association with diet and oral antidiabetic drugs
Study: 1476266
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and antidiabetic agents (Control)
Study: 1476266
Drug: Oral defibrotide
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral defibrotide
Study: 6435481
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (iv NTG) infusion at 0.5 microgram . kg‐1 . min‐1 for 20 min prior to induction of anesthesia and throughout the study
Study: 29421218
Drug: Topically delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically delivered kynurenic acid cream
Study: 27863615
Drug: Lavender essence
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender essence inhalation (2 drops at 4-5, 6-7, 8-9 cm cervical dilation)